

PRODUCT INFORMATION



FGFR3 Extracellular Domain (human, recombinant)


Item No. 37023

Overview and Properties

Synonyms: ACH, CD333, Fibroblast Growth Factor Receptor 3
Source: Recombinant human C-terminal His-tagged FGFR3 extracellular domain expressed in HEK293 cells
Amino Acids: 23-375
Uniprot No.: P22607
Molecular Weight: 39.6 kDa
Storage: -80°C (as supplied)
Stability: ≥1 year
Purity: ≥95% estimated by SDS-PAGE
Supplied in: Lyophilized from sterile PBS, pH 7.4
Endotoxin Testing: <1.0 EU/μg, determined by the LAL endotoxin assay

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Image



Lane 1: MW Markers

Lane 2: FGFR3 Extracellular Domain

SDS-PAGE Analysis of FGFR3 Extracellular Domain. This protein has a calculated molecular weight of 39.6 kDa. It has an apparent molecular weight of approximately 64.3 kDa by SDS-PAGE under reducing conditions due to glycosylation.

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/02/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Description

Fibroblast growth factor receptor 3 (FGFR3) is a growth factor receptor with roles in early mammalian skeletal development and post-embryonic linear bone growth.¹ It is composed of an N-terminal extracellular domain, which contains three immunoglobulin-like (Ig-like) domains and includes the FGF ligand-binding domain, an acidic box, and a CAM-homology domain, a transmembrane domain, and a C-terminal tyrosine kinase domain.² FGFR3 is broadly expressed in the midfacial mesenchyme and basicranial and paranasal cartilage during embryonic development but is only expressed in the perichondrium and proliferating zone chondrocytes by 10 to 13 weeks gestation.³ Upon ligand binding, FGFR3 dimerizes resulting in autophosphorylation of the tyrosine kinase domain and activation of various intracellular signaling pathways, including the ERK/MAPK pathway.⁴ Gain-of-function mutations in *FGFR3* induce achondroplasia, the most common form of dwarfism in humans.¹ Mutations in *FGFR3* also induce Muenke syndrome, a craniosynostosis with features including hearing loss, carpal and tarsal anomalies, and behavioral and developmental deficits.⁵ Cayman's FGFR3 Extracellular Domain (human, recombinant) protein consists of 364 amino acids, has a calculated molecular weight of 39.6 kDa, and a predicted N-terminus of Glu23 after signal peptide cleavage. By SDS-PAGE, under reducing conditions, the apparent molecular mass of the protein is 64.3 kDa due to glycosylation.

References

1. Narayana, J. and Horton, W.A. FGFR3 biology and skeletal disease. *Connect. Tissue Res.* **56(6)**, 427-433 (2015).
2. Bocharov, E.V., Lesovoy, D.M., Goncharuk, S.A., *et al.* Structure of FGFR3 transmembrane domain dimer: Implications for signaling and human pathologies. *Structure* **21(11)**, 2087-2093 (2013).
3. Britto, J.A., Evans, R.D., Hayward, R.D., *et al.* From genotype to phenotype: The differential expression of FGF, FGFR, and TGF β genes characterizes human cranioskeletal development and reflects clinical presentation in FGFR syndromes. *Plast. Reconstr. Surg.* **108(7)**, 2026-2039 (2001).
4. Böttcher, R.T. and Niehrs, C. Fibroblast growth factor signaling during early vertebrate development. *Endocr. Rev.* **26(1)**, 63-77 (2005).
5. Murali, C.N., McDonald-McGinn, D.M., Wenger, T.L., *et al.* Muenke syndrome: Medical and surgical comorbidities and long-term management. *Am. J. Med. Genet. A.* **179(8)**, 1442-1450 (2019).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM